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Background: The influence of prosthesis-patient mismatch (PPM) on survival after aortic valve replacement (AVR)
remains controversial. In this study, we sought to determine the effect of PPM on early (≤30 days) and late
mortality (>30 days) after AVR or AVR combined with coronary artery bypass grafting (AVR with CABG).
Methods: Between January 1998 and March 2012, 2976 patients underwent AVR (n= 1718) or AVR with CABG
(n=1258) at a single institution. PPM was defined as an indexed effective orifice area (EOAI) ≤0.85 cm2/m2 and
patients were divided into two groups based on the existence of PPM. Cumulative probability values of survival
were estimated with Kaplan-Meier method and compared between groups using Breslow test. Univariate
and multivariate independent predictors of early mortality were identified using logistic regression. Cox
proportional-hazard regression analysis was used to determine univariate and multivariate independent
predictors of late mortality.
Results: Early mortality was 6.7% in the PPM group vs 4.7% in the group with no PPM (p=0.013). Late mortality for
the PPM group at 1, 5 and 10 years was 4%, 16% and 43%, respectively. Late mortality for the group with no PPM
at 1, 5 and 10 years was 4%, 15% and 33% respectively. Independent predictors of early mortality included age,
severely impaired left ventricular (LV) function, endocarditis, renal dysfunction, chronic obstructive pulmonary
disease (COPD) and cardiopulmonary bypass (CPB) time. Multivariate independent predictors of late mortality
included age, severely impaired LV function, diabetes, peripheral vascular disease (PVD), renal dysfunction, history
of a cerebrovascular accident (CVA), CPB time and a history of previous cardiac surgery. PPM was not an
independent predictor of early or late mortality.
Conclusion: PPM is not an independent predictor of both early and late mortality after AVR or AVR combined
with CABG.
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analysisBackground
Prosthesis-patient mismatch (PPM) after aortic valve
replacement (AVR) occurs when the effective orifice
area (EOA) of the implanted valve prosthesis is too
small compared to the body surface area (BSA) of the
patient [1]. PPM is expressed by the indexed EOA
(EOAI). The EOAI is calculated by dividing the* Correspondence: b.m.j.a.koene@umcg.nl
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reproduction in any medium, provided the orcorresponding EOA of each valve type and size by
each patient’s BSA [1,2].
Several studies have shown that PPM is associated
with increased early or late mortality after AVR [3-6].
Other studies contradict these findings and report that
PPM does not have a significant impact on survival
[7-14]. Comparison of results is hampered by differences
in cut-off values for EAOI. Cut-off values in literature
range from <0.6 to <1.1 cm2/m2 [15]. Comparison of re-
sults is also hampered by the fact that some authors use
the published normal in vitro EOA values provided by
the manufacturers to identify PPM [2,14,16], whileLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Prosthetic valve distribution (n=2957)
Variable Value




St. Jude Medical Standard 899 (30.4)
ATS 442 (14.9)
St. Jude Medical Regent 93 (3.1)
St. Jude Medical HP 42 (1.4)
Biological (stented) 1487 (50.1)
Carpentier-Edwards Magna 146 (4.9)
Carpentier-Edwards Perimount 611 (20.7)
Sorin Mitroflow 325 (11.0)
Medtronic Mosaic 134 (4.5.)
St. Jude Medical Epic 176 (6.0)
Data are number of patients (%).
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identify PPM [2,5,17].
In this study, we sought to determine the effect of
PPM (cut-off value EOAI ≤0.85 cm2/m2 as described by
Pibarot and colleagues [1]) on early (≤30 days) and late
(>30 days) mortality after AVR or aortic valve replace-




This is a retrospective observational study on consecu-
tive patients. Data were obtained from the institutional
database, normally utilized for patient care. Clinical data,
echocardiographic data, catheterization data and surgical
reports were entered into the institutional database
prospectively and analyzed retrospectively. Because
standard clinical follow-up check-ups were used and
data were collected and analyzed anonymously, the need
for informed consent was waived by the Medical Ethical
Committee.
Patients
Between January 1998 and March 2012, 2976 patients
(mean age 68±11 years) underwent AVR (n=1718) or
AVR with CABG (n=1258) at a single institution using a
mechanical or a stented biological valve prosthesis. Pa-
tients who underwent AVR with implantation of a
stentless biological valve were not considered. No aortic
annular enlargement procedures were performed.
Follow-up data concerning mortality were gathered
using the databases of health insurance companies. The
remaining data that could not be retrieved from these
databases were obtained by contacting patients’ general
practitioners and if necessary by contacting local govern-
ment authorities. Nineteen patients were lost to follow-
up; mean follow-up was 5.7±3.7 years (range 0.0-14.7
years). Patients lost to follow-up were excluded from our
analysis. Late mortality was defined as death occurring
later than 30 days after surgery.
Based on the EOAI the patients were split into two
groups. Patients with an EOAI ≤0.85 cm2/m2 were
assigned to the group with PPM and patients with an
EOAI >0.85 cm2/m2 to the group without PPM.
Surgical technique
All patients underwent surgery using a standard tech-
nique. After a median sternotomy the ascending aorta
and right atrium were cannulated and normothermic
extracorporeal circulation with non-pulsatile flow was
instituted. Myocardial protection was obtained using
cold crystalloid cardioplegia (St. Thomas solution) or
warm blood cardioplegia. According to surgeon’s prefer-
ence, cardioplegia was administered in an antegradefashion through the aortic root and/or selectively in both
coronary ostia to induce and maintain cardiac arrest.
Retrograde administration of cardioplegia was not
used. Concomitant myocardial revascularization was
performed in 1258 patients. The distal anastomoses were
performed before AVR. An overview of implanted pros-
thetic valve types is shown in Table 1. No aortic annulus
enlargement techniques were used.
Prosthesis-patient mismatch (PPM)
PPM was expressed by the EOAI. The EOAI was calcu-
lated by dividing the corresponding EOA of each valve
type and size (registered in vitro values published by
each manufacturer) by each patient’s BSA [1,2]. PPM
was defined as EOAI ≤0.85 cm2/m2 [1]. Subgroup ana-
lysis of moderate PPM (EOAI >0.65 cm2/m2 and ≤0.85
cm2/m2) (n=330) and severe PPM (EOAI ≤0.65 cm2/m2)
was not performed because of the small group size of
patients with severe PPM (n=14).
Statistics
Continuous variables were expressed as mean ± SD. Cat-
egorical variables were expressed as percentages. Mean
values were compared by using independent-samples T-
test or its non-parametric alternative, the Mann–Whitney
U test, for continuous variables and Pearson’s Chi-squared
test for categorical variables.
Cumulative probability values of survival were esti-
mated with Kaplan-Meier method and compared be-
tween groups by using Breslow test.
Logistic regression was used to identify univariate pre-
dictors and multivariate independent predictors of early
mortality. Odds ratios (OR) were reported with 95%
confidence intervals (CI). Goodness of fit of the final
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goodness-of-fit test.
Cox proportional-hazard regression analysis was
used to determine univariate predictors and multi-
variate independent predictors of late mortality. Haz-
ard ratios (HR) were reported with 95% confidence
intervals (CI).
Variables considered as potential predictors for
multivariable modeling were selected by univariate
analyses (p<0.05) and were subsequently selected by
stepwise forward selection, with entry and retention
in the model set at a significance level of 0.05.
Goodness of fit of the final model was assessed with








Severely impaired (EF <30%) 92 (3.5)
Hypertension 1125 (43.1)
Diabetes Mellitus 413 (15.8)
Body weight, kg 77±13
Height, cm 170±9
Body surface area (BSA), m2 1.89±0.19
Body mass index (BMI), kg/m2 26.8±4.0
Peripheral vascular disease (PVD) 261 (10.0)
Renal dysfunction 147 (5.6)
Chronic obstructive pulmonary disease (COPD) 462 (17.7)
Cerebrovascular accident (CVA) 122 (4.7)




Concomitant coronary artery bypass grafting (CABG) 1121 (42.9)
Cardiopulmonary bypass (CPB) time, min 93±37
Aortic cross-clamp time, min 68±26
Effective orifice area (EOA), cm2 2.14±0.44
Indexed effective orifice area (EOAI), cm2/m2 1.14±0.21
Additive EuroSCORE 6±3
Logistic EuroSCORE 7.66± 8.14
Previous cardiac surgery 226 (8.6)
Mean follow-up, years 5.6±3.7
Mortality ≤30 days 100 (3.8)
Data are mean ± SD or percentage of patients.All calculations were performed using a commercially
available statistical package (SPSS 19.0; SPSS Inc.,
Chicago, IL). Statistically significant differences were
established at p<0.05.
Results
Characteristics of the patient population
After excluding 19 patients lost to follow-up, 2957 patients
were analyzed. 1701 patients underwent AVR and 1256
patients underwent AVR with CABG. 344 patients had an
EOAI ≤0.85 cm2/m2 and were allocated to the PPM group.
The remaining 2613 patients with an EOAI >0.85 cm2/m2
were allocated to the group without PPM. Patient char-
acteristics are shown in Table 2. The PPM group hadPPM P
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The patients in the PPM group had a significantly higher
average body weight (84±15 kg vs 77±13 kg,
p<0.001), a higher average body mass index (BMI)
(29.3±5.0 vs 26.8±4.0 kg/m2, p<0.001), a higher average
BSA (1.95±0.18 vs 1.89±0.19 m2, p<0.001), but there was
no significant difference in average height. In the PPM
group significantly more mechanical valve prostheses
were implanted (69.8% vs 47.3%, p<0.001), the average
cardiopulmonary bypass (CPB) time was longer (99±43
vs 93±37 min, p=0.022) and significantly more patients
had had previous cardiac surgery (17.2% vs 8.6%, p<0.001).
With regard to the distribution of comorbidities between
the two groups, only the prevalence of diabetes was sig-
nificantly higher in the PPM group (27.9% vs 15.8%,
p<0.001).
Early mortality
Early mortality was 6.7% in the PPM group vs 4.7% in
the other group (p=0.013).
The additive EuroSCORE was 6±3 in both groups
(p=0.095). The logistic EuroSCORE was 8.64±9.29 in the
group with PPM and 7.66±8.14 in the group without
PPM (p=0.146).
Predictors of early mortality
Univariate predictors of early mortality (shown in
Table 3) included age, severely impaired left ventricular








Body mass index (BMI), kg/m2
Peripheral vascular disease (PVD)
Renal dysfunction
Chronic obstructive pulmonary disease (COPD)
Cerebrovascular accident (CVA)
Mechanical prosthetic valve
Concomitant coronary artery bypass grafting (CABG)
Cardiopulmonary bypass (CPB) time, min
Aortic cross-clamp time, min
Prosthesis-patient mismatch (PPM) (cut-off ≤ 0.85 cm2/m2)
Previous cardiac surgery
CI = confidence interval; EF = ejection fraction; OR = Odds ratio; LV = left ventricularenal dysfunction, chronic obstructive pulmonary disease
(COPD), cerebrovascular accident (CVA), concomitant
coronary artery bypass grafting (CABG), CPB time, aor-
tic cross-clamp time, previous cardiac surgery and PPM.
Multivariate predictors of early mortality did not in-
clude CVA, concomitant CABG, aortic cross-clamp
time, previous cardiac surgery and the existence of PPM.
Multivariate predictors of early mortality were age, se-
verely impaired LV function, endocarditis, renal dysfunc-
tion, COPD and CPB time. This well-fitting model is
showing non-significance on the Hosmer-Lemeshow
goodness-of-fit test (p=0.308).
Late mortality
Mean follow-up was 5.7±3.7 years (range 0.0-14.7 years).
Total follow-up was 16728.6 patient-years. Late mortal-
ity for the entire group at 1, 5, and 10 years was 4%,
15% and 37%, respectively.
Late mortality at 1,5, and 10 years was 4%, 15% and
33%, respectively for the group without PPM and 4%,
16% and 43% for the PPM group.
Predictors of late mortality
The results of Cox regression analysis for late mortality
are shown in Table 4.
Univariate analysis revealed the following predictors of
late mortality: age, severely impaired LV function, dia-
betes, peripheral vascular disease (PVD), renal dysfunc-
tion, COPD, history of CVA, the use of a mechanicalys) mortality
Univariate analysis Multivariate analysis
P OR (95% CI) P OR (95% CI)
<0.001 1.04 (1.02-1.06) <0.001 1.04 (1.02-1.07)
0.058 1.42 (0.99-2.04)
0.006 2.61 (1.32-5.14) 0.026 2.24 (1.10-4.56)
0.669 1.08 (0.75-1.56)
0.351 1.24 (0.79-1.94)
0.006 2.38 (1.28-4.44) 0.006 2.85 (1.36-5.96)
0.165 0.97 (0.93-1.01)
0.052 1.65 (0.99-2.73)
<0.001 2.68 (1.54-4.64) 0.032 1.90 (1.06-3.40)
0.005 1.78 (1.19-2.68) 0.029 1.61 (1.05-2.46)
0.013 2.20 (1.18-4.08) 0.110 1.71 (0.89-3.29)
0.418 0.86 (0.60-1.24)
0.004 1.71 (1.19-2.46) 0.872 0.96 (0.62-1.51)
<0.001 1.02 (1.01-1.02) <0.001 1.01 (1.01-1.02)
<0.001 1.02 (1.01-1.02) 0.691 1.00 (0.99-1.01)
0.014 1.80 (1.13-2.88) 0.120 1.50 (0.90-2.48)
<0.001 2.96 (1.90-4.59) 0.072 1.62 (0.96-2.75)
r.
Table 4 Univariate and multivariate Cox analysis of late (>30 days) mortality
Variable Univariate analysis Multivariate analysis
P HR (95% CI) P HR (95% CI)
Age, years <0.001 1.07 (1.06-1.08) <0.001 1.84 (1.33-2.56)
Sex (female) 0.403 1.07 (0.91-1.26)
Severely impaired LV function (EF <30%) <0.001 1.93 (1.40-2.67) <0.001 2.24 (1.10-4.56)
Hypertension 0.055 1.17 (0.99-1.37)
Diabetes Mellitus <0.001 1.80 (1.49-2.17) 0.001 1.41 (1.16-1.71)
Endocarditis 0.118 0.70 (0.45-1.09)
Body mass index (BMI), kg/m2 0.837 1.00 (0.98-1.02)
Peripheral vascular disease (PVD) <0.001 2.61 (2.11-3.21) <0.001 1.99 (1.61-2.46)
Renal dysfunction <0.001 2.34 (1.76-3.13) <0.001 1.69 (1.26-2.27)
Chronic obstructive pulmonary disease (COPD) <0.001 1.64 (1.38-1.97) <0.001 1.67 (1.39-1.99)
Cerebrovascular accident (CVA) <0.001 1.88 (1.40-2.53) <0.001 1.71 (1.27-2.31)
Mechanical prosthetic valve <0.001 0.46 (0.39-0.54) 0.126 0.85 (0.70-1.05)
Concomitant coronary artery bypass grafting (CABG) <0.001 1.58 (1.35-1.84) 0.993 0.99 (0.83-1.21)
Cardiopulmonary bypass (CPB) time, min <0.001 1.01 (1.00-1.01) 0.001 1.01 (1.00-1.01)
Aortic cross-clamp time, min <0.001 1.01 (1.00-1.01) 0.385 1.00 (0.99-1.00)
Prosthesis-patient mismatch (PPM) (cut-off ≤0.85 cm2/m2) 0.032 1.26 (1.02-1.55) 0.235 1.14 (0.92-1.42)
Previous cardiac surgery <0.001 1.58 (1.25-2.00) 0.005 1.43 (1.11-.84)
CI = confidence interval; EF = ejection fraction; HR = hazard ratio; LV = left ventricular.
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clamp time, previous cardiac surgery and PPM.
Multivariate analysis revealed the following independ-
ent predictors of late mortality: age, diabetes, severely
impaired LV function, PVD, renal dysfunction, COPD, a
history of CVA, CPB time and previous cardiac surgery.
PPM was not an independent predictor of late mortality
at multivariate analysis. Goodness of fit of the final
model was assessed with the Chi-squared goodness-of-fit
test: p<0.001.
Long-term survival after AVR or AVR with CABG
Figure 1 displays the long-term survival after AVR or
AVR with CABG stratified by PPM group. Difference in
survival between the groups by Breslow test was not sig-
nificant (p=0.182).
Discussion
The most important finding of this study is that PPM is
not identified as an independent predictor of early or
late mortality after AVR or AVR with CABG. Table 5
shows the independent predictors for early or late mor-
tality after AVR or AVR with CABG. Diabetes, a history
of CVA and PVD are not predictors of early mortality,
but these comorbidities do have a detrimental impact on
long-term survival. A history of previous cardiac surgery
was an independent predictor of late mortality but not
of early mortality, indicating that re-do cardiac surgery
can be relatively safely performed with no significantnegative effect on early survival. However most patients
undergoing re-do cardiac surgery are in a more progres-
sive phase of their disease which could explain the sig-
nificant negative impact on long-term survival.
Endocarditis was only a significant independent pre-
dictor of early mortality and did not have a negative ef-
fect on long-term survival. The risk-factors age, severely
impaired LV function, renal dysfunction, COPD and
CPB time were independent predictors of both early and
late mortality.
The effect of PPM on early or long-term survival after
AVR remains controversial [18]. Several studies have
shown that PPM is a significant predictor of early or late
mortality [3-6,16,19-21], whereas other studies did not
report a significant association between PPM and early
or late mortality [7-14,22-27]. These discrepancies may
be caused by the different cut-off values for PPM
(expressed in EOAI) and the different type of EOA
values used to define PPM. Some authors use the
projected indexed EOA derived from the published nor-
mal in vivo EOA values [2,5,17], whereas others use the
in vitro manufacturer’s EOA [2,14,16]. We chose to use
the in vitro EOA values provided by the manufacturers,
since these values are uniform and publicly available for
almost each type of prosthetic valve on the market. In
our opinion, preoperative planning requires readily ac-
cessible and uniform information of all aortic valve pros-
theses currently available on the market. Manufacturer’s
EOA charts are providing this information and most
Table 5 Multivariate independent predictors
Variable Early mortality Late mortality
Age + +
Severely impaired LV function
(EF<30%)
+ +
Diabetes Mellitus − +
Endocarditis + −
Peripheral vascular disease (PVD) − +




Cerebrovascular accident (CVA) − +
Cardiopulmonary bypass (CPB) time + +
Previous cardiac surgery − +
+ = independent predictor of early and /or late mortality.
- = no independent predictor of early and/or late mortality.
Figure 1 Overall long-term survival after AVR and AVR with CABG stratified by PPM group. The dotted line is showing long-term survival
of the group without PPM and the full line is showing long-term survival of the group with PPM. There is no significant difference in survival
between the two groups (p=0.182).
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the possibility of PPM.
Valve prosthesis industry is a highly competitive market.
Although most contemporary biological and mechanical
prosthetic valve designs have excellent hemodynamic
profiles, companies want to distinguish their products with
demonstrable specifications. It would be illusory to deny
the existence of PPM completely, but marketing may have
caused too much attention concerning this topic. Perhaps
the issue of PPM is partially an industry driven hype.
An important limitation is the retrospective design of this
study. Although both study populations were homogeneous
for most risk-factors, some baseline patient characteristics
were significantly different between the two groups. We
were not able to do subgroup analyses of moderate and se-
vere PPM due to the lack of patients with severe PPM. This
can be explained by our surgical strategy to implant the big-
gest valve possible and to use prosthetic valves with optimal
hemodynamic profiles in patients with small annular sizes,
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severe PPM is extremely rare when using this strategy even
without using aortic annular enlargement techniques.
Other studies confirm that the incidence of severe PPM
is low [22,28]. In addition, the primary end-point was
all-cause mortality. We were not able to retrieve the
cause of death that might be equally important.
Conclusions
In conclusion, our findings indicate that PPM is not an
independent predictor for early or late mortality after AVR
or AVR with CABG. The outcome of this study puts the
importance of PPM once again into perspective.
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